About TeloiX

What TeloiX is

TeloiX is a reference site built around a mechanism–intervention–study graph for telomere biology (telomere attrition, telomerase, shelterin, the Hayflick limit, ALT) and the interventions claimed to lengthen telomeres or activate telomerase. It is deliberately narrow: a small number of landmark interventions and studies, presented with source references and stated limitations, rather than a broad advice article. It reports what each study actually measured — telomere length? telomerase activity? a clinical outcome? — in which population. Telomere-driven replicative senescence is cross-referenced to the senesiq cluster, not duplicated.

The central honesty facts

None of the study records covered here establishes a healthy-aging human lifespan benefit. The human evidence here is real but qualified: a telomere-length biomarker RCT (TA-65), clinical outcomes in a rare telomere disease (danazol, nandrolone), and a small cancer-cohort pilot (Ornish). Beyond that, two truths govern every page: telomere length is a contested aging biomarker (longer is not simply healthier), and telomerase activation is not risk-free — the FDA-approved telomerase inhibitor, imetelstat (2024), inhibits telomerase to treat cancer, the opposite direction from anti-aging "activation."

Commercial conflict-of-interest note

The most-cited human "telomerase activator" data on this site — the TA-65 telomere-length RCT (Salvador 2016) and the earlier immune study (Harley 2011) — were produced by authors with a direct commercial interest in the product. TA-65 is sold by T.A. Sciences; Calvin Harley (a TA-65 co-inventor and long-time commercial proponent) and other T.A. Sciences–affiliated authors appear on those papers. This does not by itself invalidate the results, but it is a material conflict of interest that a reader weighing a supplement marketed on telomere claims must know. TeloiX has no commercial relationship with T.A. Sciences or any product mentioned.

Publisher / editorial identity

Nabus AS is the editorial owner and publisher. This site does not attribute content to any named individual author or reviewer; no person is fabricated for E-E-A-T purposes. When a named, verifiable human reviewer is assigned to a page in a future revision, that attribution will be added — and not before.

Editorial sourcing process

Pages are generated from structured evidence records. Automated consistency and language checks are technical checks, not clinical review or proof that every scientific claim is correct. No named medical reviewer is attributed. Source-publication identifiers and claim-level evidence must be checked separately; confirming a DOI does not establish the accuracy of a result summary.

Sourcing standard

Every study record carries five visible qualifiers: species/population; exposure, route and schedule; comparator and duration; endpoint and numeric result; and what the study did NOT establish. Every record carries a verification_status, and every trial/registry identifier a citation_status. Journal/volume/DOI were confirmed via Crossref and trial status via the ClinicalTrials.gov v2 API where an identifier was resolvable. An identifier that cannot be confirmed against the primary record is left empty and named as unconfirmed in the record itself — it is never presented as verified and never filled in from a secondary source. See the methodology page.

Monetization

One intervention page — TA-65 (cycloastragenol) — carries an affiliate link. The link is a disclosed retailer search. It does not verify the product or formulation used in a particular trial; retailers control availability and purchase terms. Prescription and investigational intervention pages carry no purchase links. The TA-65 page describes the trial authors' reported commercial interests. This is still a reference resource, not a shopping guide; see the affiliate disclosure.

Prohibited claim language

The editorial process blocks a fixed list of prohibited marketing phrases — for example, claims that lengthening telomeres turns back your biological clock, that a supplement is a telomerase ‘fountain of youth’, that telomerase activation is risk-free, or that any compound here has a proven human lifespan effect — via an automated pattern check run at build time. See generators/check_claim_patterns.py.

Licensing & data enquiries

The structured telomere evidence dataset behind this site is independently sourced. For dataset-licensing or research-data enquiries, use the form below. This is an inbound enquiry channel only: submitting it does not buy coverage, placement, or a change to any record, and no sponsored placements or advertising appear anywhere on this site. One intervention page — TA-65 (cycloastragenol) — carries an affiliate link.

Version history